Proton therapy reirradiation confers survival benefits in head and neck cancer, with caveat

27 Jan 2023
Proton therapy reirradiation confers survival benefits in head and neck cancer, with caveat

Treatment with proton therapy reirradiation (PT-ReRT) for head and neck cancer appears to improve survival outcomes in patients, but this benefit comes with substantial toxic effects, according to a study.

The retrospective cohort study included 242 patients (median age 63 years, 75.6 percent men) with head and neck squamous cell carcinoma who underwent PT-ReRT. Researchers looked at patient, clinical, and treatment characteristics and assessed survival outcomes including local control (LC), local-regional control, distant metastatic control, progression-free survival (PFS), and overall survival (OS).

Of the patients, 206 patients (85.1 percent) had recurrent disease, 231 (95.9 percent) had a Karnofsky performance status score of 70 or higher, and 145 (59.9 percent) had at least a 10–pack-year smoking history. Median follow-up was 12.0 months for all patients and 24.5 months for survivors.

Patients in the fractionated group received a median PT-ReRT dose of 70 cobalt gray equivalents (CGE), while those in the quad shot cohort received a median of 44.4 CGE. The median interval between radiation courses was 22 months.

The 1-year LC and OS rates were 71.8 percent (95 percent confidence interval [CI], 62.8–79.0) and 66.6 percent (95 percent CI, 58.1–73.8) in the fractionated group, respectively. The corresponding 1-year LC and OS rates in the quad shot group were 61.6 percent (95 percent CI, 46.4–73.6) and 28.5 percent (95 percent CI, 19.4–38.3).

Improved OS with PT-ReRT was predicted by Higher Karnofsky performance status scores (hazard ratio [HR], 0.50, 95 percent CI, 0.25–0.99; p=0.046) and receipt of salvage surgery prior to PT-ReRT (HR, 0.57, 95 percent CI, 0.39–0.84; p=0.005). On the other hand, receipt of quad shot was associated with worse OS (HR, 1.97, 95 percent CI, 1.36–2.86; p<0.001).

There were 73 cases of grade 3 and six cases of grade 4 early toxic effects. In addition, 79 potential grade 3, four grade 4, and five grade 5 late toxic effects were documented.

JAMA Netw Open 2023;6:e2250607